Discovery of Anti-Tumoral Indoles with One-Pot Preparation and Enhanced Anti-Tumor Activity

Strategic Insights -

Researchers from the Capital Medical University, College of Pharmaceutical Sciences in Beijing, People's Republic of China, have made significant findings in the discovery of anti-tumoral indoles. A series of benzyl 1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo[3',4':1,2]pyridin[3,4-b]indole-2-substituted acetates (2a-n) were prepared via one-pot-preparation, demonstrating enhanced anti-tumor activity against various cancer cell lines. The study's results were published in the Bioorganic & Medicinal Chemistry journal.

Key Takeaways:

  • A series of benzyl 1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo[3',4':1,2]pyridin[3,4-b]indole-2-substituted acetates (2a-n) were synthesized through one-pot-preparation, showcasing their potential as anti-cancer agents.
  • The IC(50) values of 2a-n in vitro against human lung carcinoma, prostate cancer, nasopharyngeal carcinoma, vincristine-resistant KB subline, and human breast carcinoma cells ranged from 40 nM to 60 microM.
  • Four compounds (2e, g, h, i) significantly inhibited tumor growth in the Sarcoma 180 (S180) tumor-bearing mouse model, with the most potent compound (2h) demonstrating efficacy comparable to 1.0mg/kg of doxorubicin.
  • Unlike doxorubicin, the compounds (2e, g, h, i) did not induce treated S180 mice to exhibit organ atrophy, body emaciation, or neurotoxic response up to 500mg/kg.
  • Fluorescence quenching experiments and automated flexible ligand docking confirmed the interaction of 2a-n with DNA.
  • 3D QSAR analysis demonstrated a correlation between the IC(50) values of 2a-n against prostate cancer cells and the structures and conformations of their side chains.

Statistics:

  • IC(50) values ranged from 40 nM to 60 microM against various cancer cell lines.
  • Four compounds (2e, g, h, i) demonstrated significant anti-tumor activity in the S180 tumor-bearing mouse model.
  • The most potent compound (2h) exhibited efficacy comparable to 1.0mg/kg of doxorubicin.
  • The compounds (2e, g, h, i) did not induce treated S180 mice to exhibit organ atrophy, body emaciation, or neurotoxic response up to 500mg/kg.

Sources:

  • Liu, J., et al. (2010). Benzyl 1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo[3',4':1,2]pyridin[3,4-b]indole-2-substituted acetates: One-pot-preparation, anti-tumor activity, docking toward DNA and 3D QSAR analysis. Bioorganic & Medicinal Chemistry, 18(5), 1910-1917.